Doximity, Inc. (DOCS) shares plunged nearly 35% in premarket trading Friday before settling at $27.38, representing a daily decline of almost 18%. The sharp selloff followed the company’s fiscal third-quarter earnings report, which was overshadowed by disappointing revenue guidance for the upcoming quarter.
| Current Price | $27.38 |
| Daily Change | -17.83% 🔴 |
| Day Range | $23.66 – $27.50 |
| 52-Week Range | $23.66 – $85.21 |
| Volume | 4.5M+ |
Investors reacted negatively to management's outlook, which cited significant uncertainty among pharmaceutical clients regarding regulatory changes.
While the company exceeded analyst estimates for the most recent quarter, the downward revision in future expectations triggered a massive wave of selling as the stock hit its lowest levels since late 2023, reflecting the inherent risks often found when investing in stocks.
According to the company's newsroom, the board authorized a new $500 million stock repurchase program to help stabilize shareholder value.
However, this move was not enough to offset concerns regarding a slowdown in pharmaceutical spending and lengthened sales cycles.
Key Takeaways
- DOCS stock fell nearly 18% today after a 35% premarket plunge
- Fiscal Q4 revenue guidance of $143 million to $144 million missed market expectations
- Multiple analysts slashed price targets, including Piper Sandler dropping from $70 to $40
- Management cited pharmaceutical client uncertainty due to the Most Favored Nation (MFN) agreement
- Doximity authorized a new $500 million share buyback program despite the guidance miss
| Event Impact Analysis: Q3 Results vs. Guidance | |
|---|---|
| Q3 Revenue | $185.1M |
| Q3 EPS | $0.46 |
| Q3 EPS Beat % | +15% 🟢 |
| Q4 Revenue Guidance | $143M – $144M |
| Share Repurchase Program | $500M |
Why Did Doximity (DOCS) Stock Plunge 35% Today?
The primary driver of the collapse was a significant gap down during the premarket session on February 6, 2026. The stock opened at $23.69, a steep drop from its prior close of $33.32.
Trading volume surged during this period, with more than 4.5 million shares changing hands as investors rushed to exit positions.
This downward movement wiped out months of gains, pushing the stock toward its 52-week low of $23.66.
The volatility reflects investor anxiety over the company’s ability to maintain its growth trajectory in a shifting regulatory landscape for healthcare providers and pharmaceutical manufacturers.
What Catalyst Sparked Doximity's Massive Sell-Off?
The selloff was sparked by a disappointing financial outlook for the fiscal fourth quarter and full year 2026. Management projected Q4 revenue between $143 million and $144 million, which fell short of analyst projections.
For the full fiscal year, the company expects revenue to land between $642.5 million and $643.5 million.
Company board member Timothy Cabral noted that multiple customers are deploying a lower percentage of their annual budgets upfront than they have historically.
This “macro-driven caution” is largely attributed to the Most Favored Nation (MFN) agreement and other policy changes that have increased regulatory pressure on pharmaceutical spending.
How Are Analysts Reacting to Doximity's Outlook?
Wall Street analysts responded to the guidance with a series of aggressive price target cuts. Investors often look to these stock analyst ratings to gauge sentiment during periods of high volatility.
Piper Sandler analyst Jessica Tassan slashed her target from $70 to $40, citing weak bookings in the second and third quarters and a 5% slowdown in market growth.
Wells Fargo also lowered its target to $45 from $55, while Needham dropped its projection to $55 from $75.
In a contrasting move, JPMorgan Chase & Co. upgraded the stock to a “Neutral” rating on February 6.
While some firms maintained positive ratings, the general consensus shifted toward a more cautious stance as analysts weighed the company’s high margins against slowing revenue growth and increased competition.
Doximity's Q3 Performance: A Mixed Bag Before the Plunge?
Lost in the guidance-driven panic was a relatively strong fiscal third-quarter performance. Doximity reported an EPS of $0.46, which beat analyst expectations of $0.40 by 15%.
Total revenue for the quarter reached $185.1 million, marking a 10% increase year-over-year and exceeding projections by $3.5 million.
However, some underlying metrics showed signs of strain. Net income fell to $61.6 million compared to $75.2 million in the same quarter the previous year.
Additionally, operating cash flow and free cash flow decreased by 7% and 8% respectively.
These declines in profitability and cash generation likely compounded the negative sentiment surrounding the company's forward-looking guidance.
How Does DOCS's Decline Compare to its Industry Peers?
Doximity’s nearly 18% drop represents a significant underperformance compared to the broader Health Information Services industry. While Doximity plummeted, the industry average change today was a positive 0.4%.
Peer companies showed mixed but generally more stable results. GoodRx Holdings (GDRX) rose nearly 7%, and HeartFlow (HTFL) gained almost 8%.
In contrast, Omnicell (OMCL) fell over 5% and Claritev Corporation (CTEV) declined more than 2%.
The disparity suggests that Doximity’s struggles are specific to its client base rather than a sector-wide downturn, a distinction often found when using stock screener apps to compare industry peers.
| Company | Symbol | Daily Change | Market Cap |
|---|---|---|---|
| GoodRx Holdings | GDRX | +6.99% 🟢 | – |
| HeartFlow | HTFL | +7.66% 🟢 | – |
| Omnicell | OMCL | -5.64% 🔴 | – |
| Industry Avg | – | +0.44% | – |
| Doximity | DOCS | -17.83% 🔴 | – |
Market Cap data not available for peers.
What Should Investors Watch Next for Doximity?
The execution of the newly authorized $500 million stock repurchase program will be a key factor for investors to monitor. This program signals management's belief that the current share price may be undervalued.
CEO Jeff Tangney also highlighted that over 300,000 users are now engaging with the platform’s new AI features, which could drive long-term engagement.
Investors should also look for signs of a recovery in pharmaceutical bookings. Despite the cautious guidance, Timothy Cabral mentioned that January pharma bookings growth was the best the company has seen since going public.
Whether this momentum can offset the regulatory headwinds of the MFN agreement remains the central question for the company's fiscal 2027 performance and its status among growth stocks.
The Bottom Line
Doximity finds itself at a crossroads as it balances record user engagement and a successful AI rollout against a tightening pharmaceutical spending environment.
The massive selloff underscores how sensitive the market has become to guidance misses, even when a company beats current-quarter earnings.
| 🟢 Bull Case | 🔴 Bear Case |
|---|---|
| • Q3 EPS beat expectations by 15% | • Disappointing Q4 revenue guidance |
| • 300K+ users adopting new AI features | • Regulatory MFN agreement headwinds |
| • Authorized $500M stock buyback | • Lengthened sales cycles/delayed deals |
| • Record January pharma bookings growth | • Declining net income & cash flow |
While the company remains highly profitable with an Adjusted EBITDA margin of 60%, the immediate outlook is clouded by regulatory uncertainty and delayed client budgets.
Investors will likely remain cautious until the company can demonstrate that its January booking momentum is a sustainable trend rather than a temporary outlier.
